PMV Pharmaceuticals
PMVP
64 hedge funds and large institutions have $45.9M invested in PMV Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 9 closing their positions.
0% more capital invested
Capital invested by funds: $45.8M → $45.9M (+$92.8K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.03% less ownership
Funds ownership: 69.31% → 64.28% (-5%)
7% less funds holding
Funds holding: 69 → 64 (-5)
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$642K |
| 2 |
BC
BIT Capital
Berlin,
Germany
|
+$364K |
| 3 |
VA
Verdad Advisers
Boston,
Massachusetts
|
+$234K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$171K |
| 5 |
Two Sigma Investments
New York
|
+$89.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.17M |
| 2 |
Morgan Stanley
New York
|
-$1.06M |
| 3 |
LP
Longaeva Partners
Chicago,
Illinois
|
-$685K |
| 4 |
EP
Eversept Partners
New York
|
-$587K |
| 5 |
SCM
Sio Capital Management
New York
|
-$568K |
PMVP Hedge Fund Activity: Q2 2026 in Review
64 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q2 2026, worth a combined $45.9M — up 0.2% from $45.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PMVP and 4 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 14 added.
The largest buyer was Adage Capital Partners, adding an estimated $642K. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $1.17M.
- 64 institutional investors held PMV Pharmaceuticals (PMVP) as of Q2 2026, down from 69 in Q1 2026.
- Funds reported $45.9M of PMV Pharmaceuticals stock for Q2 2026, up 0.2% quarter-over-quarter.
- 4 funds opened new PMV Pharmaceuticals positions in Q2 2026 and 9 closed out, a net change of -5 holders.
- The largest PMV Pharmaceuticals buyer in Q2 2026 was Adage Capital Partners, an estimated $642K added.
- The largest PMV Pharmaceuticals seller in Q2 2026 was ArrowMark Colorado Holdings, an estimated $1.17M sold.
Based on aggregated 13F filings for Q2 2026.